2024-07-23129478 KB137页25
2024-07-242051.69 MB18页25
2024-07-25144608.33 KB1页25
2024-07-251352.12 MB4页25
2024-07-251082.25 MB2页25
2024-07-25172576.6 KB8页25
2024-07-25112499.72 KB8页25
ESHStatementESHPositionPaper:Renaldenervation^aninterventionaltherapyofresistanthypertensionRolandE.Schmiedera,JosepRedonb,GuidoGrassic,k,SverreE.Kjeldsend,GiuseppeManciae,KrzysztofNarkiewiczf,GianfrancoParatig,LuisRuilopeh,PhilippevandeBornei,andCostasTsioufisjExpertsfromtheEuropeanSocietyofHypertensionAccordingtotheEuropeanSocietyofHypertensionpreparedthispositionpaperinordertosummarizecurren... 2024-07-25196155.54 KB5页25
2024-07-26190392.7 KB8页25
2024-07-26167334.04 KB4页25
2024-07-26911.71 MB3页25
2024-07-26982.64 MB2页25
2024-07-26809.23 MB52页25
2024-08-212012.14 MB27页25
2024-07-181965.42 MB34页24
2024-07-171851.39 MB31页24
“中国新靶点”数据分析赋能未满足临床需求药物研发王中健博士享融智云CEOhttps://www.pharnexcloud.com/目录CONTENTS01新药研发现状及热门靶点概述02深入挖掘“中国新靶点”03各适应症“中国新靶点”分析04总结https://www.pharnexcloud.com/全球新药数量分阶段统计124,521国内首家研发企业43,909国外首家研发企业80,61215,5905,0224,9266,1163,0271,413774787药物发现12,5634,1521,6155,329334临床前4604723,609II期临床1,281... 2024-07-172058.18 MB31页24
2024-07-1759847.25 KB2页24
2024-07-171351.32 MB23页24
2024-07-171221.34 MB30页24
